MiSight® 1 day (CooperVision) and Stellest® HALT lenses (EssilorLuxottica) represent two of the most evidence-supported optical interventions for myopia control in children. Both have high-quality RCT data, but their mechanisms, patient profiles, and practical considerations differ meaningfully.
| Metric | MiSight® 1 day | Stellest® (HALT) |
|---|---|---|
| AL reduction vs untreated | 55% | 67% |
| Primary RCT | Chamberlain et al. 2019 | Bao et al. 2022 |
| Journal | Optometry & Vision Science | JAMA Ophthalmology |
| Study duration | 3 years | 2 years |
| Modality | Soft daily disposable contact lens | Spectacle lens (HALT design) |
| Minimum age (typical) | 8 years | 6 years |
| Compliance dependency | High (contact lens wear hours) | Moderate (spectacle wear hours) |
MiSight® 1 day uses a dual-focus design with alternating distance correction zones and treatment (myopic defocus) zones. The treatment zones create simultaneous myopic defocus across the peripheral retina, which is hypothesized to slow the scleral growth signal driving axial elongation.
Stellest® HALT (Highly Aspherical Lenslet Target) creates a volume of myopic defocus in front of the retina using 11 rings of non-contiguous aspherical lenslets. Unlike MiSight, the lenslets create a conical volume of focus rather than discrete rings, covering a broader area of the retinal periphery.
Choose MiSight® when: The child is suitable for contact lens wear (typically 8+), has good hygiene habits and parental support for daily lens care, and the family prefers daily disposables over spectacles.
Choose Stellest® when: The child is too young for contact lenses (under 8), contact lens tolerance is poor, compliance with lens care is a concern, or spectacle wear is preferred for simplicity.
Both are appropriate as monotherapy for moderate progressors. For high-risk patients (AL >95th percentile, growth rate >0.40mm/year (a commonly used clinical trigger; not a formal IMI 2025 guideline cutoff), young age of onset), combination therapy with low-dose atropine may provide additional benefit beyond either modality alone.
MyopiaTracker allows you to input your patient's age, current axial length, and prior AL to generate a projected outcome with MiSight®, Stellest®, and all other modalities side by side — using the RCT efficacy values above. Free, no login required.
Plot axial length against normative curves, compare treatment outcomes, and generate a parent-ready report — in under 30 seconds. Free, no login required.
Start with a Sample Patient →This page is provided for educational purposes. MyopiaTracker is a clinical decision support tool and does not constitute medical advice, diagnosis, or treatment. All efficacy values are population averages from published RCTs; individual patient outcomes vary. MiSight® is a registered trademark of The Cooper Companies, Inc. Stellest® is a registered trademark of Essilor International. MiyoSmart® is a registered trademark of Hoya Corporation.